An announcement from Shanghai Pharmaceuticals Holding Co.,Ltd. (SH: 601607) reveals that its subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd., has recently obtained a Drug Registration Certificate from the National Medical Products Administration.

The certificate, numbered 2026S02303, grants approval for the production of Vigabatrin Oral Solution Powder.

This medication is indicated for the treatment of infantile spasms.